Almon Healthcare, an Indian active pharmaceutical ingredient (API) maker, knowingly used mislabeled, untested raw material and shipped affected drugs to the U.S.
What happened
FDA inspected the facility from February 9 to 13, 2026 and found that the quality unit intentionally accepted supplier lots deliberately mislabeled as another material, did not perform identity testing, and used the material in multiple API batches shipped to the U.S. FDA also found unvalidated test methods and inadequate cleaning of shared equipment, including visible particles and liquid on product-contact surfaces.
What FDA found
The quality unit did not check that incoming raw materials were what they claimed to be and knowingly accepted mislabeled material from a supplier, then used it in APIs sent to the U.S.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The firm did not validate or verify several analytical test methods, including stability-indicating methods, and its transferred method missed impurities that the contract lab's validated method found.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The firm did not adequately clean shared API equipment and had no formal cleaning validation or maximum carryover limit, with visible residues found on product-contact surfaces.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
What FDA wants
FDA tells Almon to correct the deviations promptly and respond in writing within 15 working days with assessments and corrective-action plans for its quality unit, test methods, and cleaning; if it cannot finish, it must explain why and give a completion schedule.
Who should pay attention
- brands and compounders buying APIs from this firm
- U.S. drugmakers relying on Indian API suppliers
- contract manufacturers and distributors handling affected lots
This is a summary. Read the original letter on fda.gov.